NCT03199885 2025-12-30Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast CancerNational Cancer Institute (NCI)Phase 3 Completed190 enrolled 12 charts
NCT02003209 2025-08-08Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast CancerNational Cancer Institute (NCI)Phase 3 Completed315 enrolled 11 charts